Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H17Cl2NO |
| Molecular Weight | 286.197 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC[C@@]12C[C@@]1(CCNC2)C3=CC(Cl)=C(Cl)C=C3
InChI
InChIKey=ICXJGCSEMJXNQF-KBPBESRZSA-N
InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1
| Molecular Formula | C14H17Cl2NO |
| Molecular Weight | 286.197 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:42:29 UTC 2023
by
admin
on
Sat Dec 16 11:42:29 UTC 2023
|
| Record UNII |
9DE44WJ46X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9DE44WJ46X
Created by
admin on Sat Dec 16 11:42:30 UTC 2023 , Edited by admin on Sat Dec 16 11:42:30 UTC 2023
|
PRIMARY | |||
|
GSK1360707F
Created by
admin on Sat Dec 16 11:42:30 UTC 2023 , Edited by admin on Sat Dec 16 11:42:30 UTC 2023
|
PRIMARY | |||
|
DTXSID601029661
Created by
admin on Sat Dec 16 11:42:30 UTC 2023 , Edited by admin on Sat Dec 16 11:42:30 UTC 2023
|
PRIMARY | |||
|
24802841
Created by
admin on Sat Dec 16 11:42:30 UTC 2023 , Edited by admin on Sat Dec 16 11:42:30 UTC 2023
|
PRIMARY | |||
|
1013098-04-8
Created by
admin on Sat Dec 16 11:42:30 UTC 2023 , Edited by admin on Sat Dec 16 11:42:30 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: GlaxoSmithKline; Class: Antidepressant, Anxiolytic, Small molecule; Mechanism of Action: Adrenergic uptake inhibitor, Dopamine uptake inhibitor, Serotonin uptake inhibitor; Orphan Drug Status: No; On Fast track: No; Highest Development Phases: Phase I for Anxiety disorders, Depressive disorders; Most Recent Events: 30 Apr 2009 Phase-I clinical trials in Depressive disorders in United Kingdom (PO), 30 Apr 2009 Phase-I clinical trials in Anxiety disorders in United Kingdom (PO)
|
